Search Result

Results for "

tumor targeting agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (2) ADC Antibody (2) ADC Payload (2) Adenosine Receptor (1) Akt (2) Antibody-Drug Conjugates (ADCs) (1) Antifolate (1) Apoptosis (30) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Autophagy (5) Bacterial (2) Bcl-2 Family (4) Biochemical Assay Reagents (7) c-Kit (2) c-Met/HGFR (1) c-Myc (2) Carbonic Anhydrase (1) Caspase (6) CD20 (1) CD3 (1) CDK (2) Checkpoint Kinase (Chk) (2) CMV (1) Collagen (1) Complement System (1) CRM1 (1) Cytochrome P450 (3) DNA Alkylator/Crosslinker (3) DNA Stain (1) DNA/RNA Synthesis (8) Drug Derivative (3) Drug Intermediate (3) Drug Isomer (1) Drug Metabolite (1) EGFR (6) Ephrin Receptor (2) Epigenetic Reader Domain (3) ERK (1) Estrogen Receptor/ERR (1) FAP (5) FKBP (1) FLT3 (1) Fluorescent Dye (2) Fungal (2) Gli (1) GLUT (1) Glycoprotein VI (1) Glycosidase (1) GnRH Receptor (1) HDAC (4) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (1) IGF-1R (1) Integrin (4) Isotope-Labeled Compounds (3) JAK (1) JNK (1) Ligands for Target Protein for PROTAC (1) Liposome (1) MDM-2/p53 (3) MicroRNA (1) Microtubule/Tubulin (12) MMP (1) Molecular Glues (1) Necroptosis (2) NF-κB (6) NO Synthase (1) OAT (1) P-glycoprotein (1) p38 MAPK (1) Parasite (1) PD-1/PD-L1 (2) PDGFR (2) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Photosensitizer (1) PROTACs (2) Proteasome (4) PSMA (1) Pyruvate Carboxylase (PC) (1) Quinone Reductase (1) Radionuclide-Drug Conjugates (RDCs) (8) Raf (1) Ras (2) Reactive Oxygen Species (ROS) (4) Reference Standards (2) RET (1) ROS Kinase (1) Smo (1) Somatostatin Receptor (2) STAT (1) Survivin (1) Thymidylate Synthase (1) Tie (1) Tim3 (1) Topoisomerase (6) TREM receptor (4) Trk Receptor (2) VEGFR (6) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (127) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Labeling and Fluorescence Imaging (1) DBCO (1) Azide (1) Alkynes (1)
Oligonucleotides:	Pegylated Lipids (1) Aptamers (1) Polymers (1)

123

Inhibitors & Agonists

Bibliotecas de Screening

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Large Tumor Suppressor (LATS) TNF Receptor BRK

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-10227

Bortezomib Maximum Cited Publications 248 Publications Verification PS-341; LDP-341; NSC 681239	Proteasome NF-κB Apoptosis Autophagy TREM receptor	Cancer
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P9968

Nimotuzumab 1 Publications Verification h-R3	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-W053583

Tetraxetan 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-19542

C6 Ceramide 3 Publications Verification C6-Cer; N-Hexanoylsphingosine	Apoptosis	Cancer
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-172494

DSPE-PEG2000-iRGD	Liposome Integrin Drug Intermediate Complement System	Cancer
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-114243

DpC	NF-κB JNK Caspase Apoptosis	Neurological Disease Cancer
DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .

HY-139401

FAPI-34	FAP	Cancer
FAPI-34 is a SPECT imaging agent targeting FAP. FAPI-34 specifically binds to FAP, is highly internalized by FAP-expressing cells, accumulates in FAP-expressing tumor lesions, and shows low uptake in normal tissues except the kidneys. FAPI-34 is applicable for tumor-related research .

HY-124012

PCNA-I1	DNA/RNA Synthesis Apoptosis	Cancer
PCNA-I1 is a selective small molecule inhibitor targeting proliferating cell nuclear antigen (PCNA) with anticancer activity. PCNA-I1 can stabilize the PCNA trimer structure (Kd=0.14-0.41μM), reduce its binding to chromatin, induce tumor cell cycle arrest, inhibit DNA replication and repair, and enhance the anti-tumor effect of DNA damaging agents. PCNA-I1 can be used in the study of targeted therapy for prostate cancer, lung cancer and other tumors .

HY-16350

BOLD-100 1 Publications Verification NKP-1339; IT-139; KP-1339	DNA/RNA Synthesis Apoptosis	Cancer
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-D1716

S0456	Fluorescent Dye Drug Intermediate	Cancer
S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents .

HY-W250149

Chlorophosphonazo III	Biochemical Assay Reagents	Cancer
Chlorophosphonazo III is a cell membrane-permeable contrast agent and spectrophotometric reagent. Chlorophosphonazo III forms stable 1:1 complexes with intracellular calcium, magnesium, uranium, titanium, zirconium, thorium, scandium, equivalent actinides and protactinium. Chlorophosphonazo III generates photoacoustic signals correlated with Ca ²⁺ concentrations, which is applicable for imaging 3D tumor cell cultures and tumor spheroids. Chlorophosphonazo III exhibits no cytotoxicity, can be used for spectrophotometric detection of target ions, and the absorbance of its complexes remains stable for up to one week within the pH range of 2.2 to 7.0 .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	Peptide-Drug Conjugates (PDCs) GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .

HY-147918

Anticancer agent 73	DNA/RNA Synthesis	Cancer
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .

HY-158067

Deferoxamine-DBCO DFO-DBCO	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-P2955

Heparinase II	Glycosidase	Cancer
Heparinase II is a glycosidase targeting heparin and heparan sulfate. Heparinase II is promising for research of glycosaminoglycan structure-function analysis, anticoagulant agents and tumor microenvironment modulation .

HY-P10579

123B9 1 Publications Verification	Ephrin Receptor	Cancer
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a K_d value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .

HY-19916

Lisavanbulin BAL-101553	Microtubule/Tubulin Checkpoint Kinase (Chk)	Cancer
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .

HY-156675A

Plecstatin-1 hydrochloride 1 Publications Verification	Microtubule/Tubulin	Cancer
Plecstatin-1 hydrochloride is an anticancer agent containing organoeuropium. Plecstatin-1 hydrochloride selectively targets plectin, a scaffolding protein and cellular connector, in tumor spheroids .

HY-139852

PLAP-IN-1	Phosphatase	Cancer
PLAP-IN-1 is a selective PLAP inhibitor with an IC₅₀ of 0.032 μM. PLAP-IN-1 acts as a tumor-targeting agent; its fluorescein-conjugated derivative specifically binds to PLAP-positive tumor cells in vitro and targets cervical cancer in mouse xenograft models. PLAP-IN-1 can be used in the research of cervical cancer and ovarian cancer .

HY-132134

MC-Gly-Gly-Phe-Gly-PAB-MMAE	Biochemical Assay Reagents	Cancer
MC-Gly-Gly-Phe-Gly-PAB-MMAE (Compound SMP-81641) is a control targeted linker-agent conjugate. MC-Gly-Gly-Phe-Gly-PAB-MMAE can be used in tumor research .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P991742

LY4101174 Antibody 15A7.5; ETx-22 Antibody	ADC Antibody	Cancer
LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .

HY-102001

Tomaymycin DM	ADC Payload	Cancer
Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).

HY-15855

Fosbretabulin tromethamine	Microtubule/Tubulin	Cancer
Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-W582504

Chlorotris(triphenylphosphine)copper CuCl(TPP)3	DNA Stain Bacterial Fungal	Infection Cancer
Chlorotris(triphenylphosphine)copper (CuCl(TPP)₃) is a *DNA*-targeted metal complex. Chlorotris(triphenylphosphine)copper involves non-covalent interactions (such as groove binding mode) through the copper(I) center to affect DNA function, showing inhibitory activity against bacteria, fungi, and tumor cells. Chlorotris(triphenylphosphine)copper is promising for research of antibacterial, antitumor, and antioxidant agents .

HY-106168

Thymectacin NB1011	Thymidylate Synthase	Cancer
Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS). Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin) .

HY-19916A

Lisavanbulin dihydrochloride BAL-101553 dihydrochloride	Microtubule/Tubulin Checkpoint Kinase (Chk)	Cancer
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma .

HY-13622A

Elomotecan BN 80927 free base	Topoisomerase	Cancer
Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II .

HY-P9968A

Nimotuzumab (powder)	EGFR	Cancer
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-13622

Elomotecan hydrochloride BN 80927	Topoisomerase	Cancer
Elomotecan hydrochloride (BN 80927) is a potent inhibitor of topoisomerases I and II. Elomotecan hydrochloride (BN 80927) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan hydrochloride (BN 80927) reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II .

HY-P991395

TQB2618	Tim3	Cancer
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .

HY-W520748

MJC13	FKBP	Cancer
MJC13 is an *FKBP52*-targeted agent with anti-tumor activity that can be used in prostate cancer research .

HY-175171

Anticancer agent 276	Topoisomerase VEGFR c-Met/HGFR EGFR Estrogen Receptor/ERR	Cancer
Anticancer agent 276 (Compound 5) is a multi-target anticancer agent. Anticancer agent 276 has a potent anticancer activity against human tumor cells with IC₅₀s of 6.90 and 4.48 μM for HEPG2 and MCF7 cells, respectively. Anticancer agent 276 shows strong and stable interactions across multiple targets, including Topoisomerase II, VEGFR2, c-Met, EGFR and ERα .

HY-121561

Nitrocaphane At-1258; Nsc 245413	DNA/RNA Synthesis	Cancer
Nitrocaphane (At-1258) is an antineoplastic agent whose target of action is DNA. Nitrocaphane has a broad antineoplastic spectrum. Nitrocaphane's cytotoxicity on HEp-2 cells can be enhanced by hyperthermia. Nitrocaphane can be used in the research of tumors such as malignant trophoblastic tumors .

HY-151207

Anticancer agent 81	Apoptosis ADC Payload	Cancer
Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the *antibody–agent* conjugate (ADC*) T-PBA. T-PBA maintained its mode of target* and internalization ability of Trastuzumab .

HY-N0093A

Ancitabine Cyclocytidine; Cyclo-CMP	DNA/RNA Synthesis CMV Autophagy	Cancer
Ancitabine is the precursor of the anticancer agent Cytarabine (HY-13605), which targets targets related to cell metabolism and proliferation. Ancitabine can inhibit tumor cell proliferation, interfere with the DNA synthesis process of tumor cells, and prevent cell division. Under alkaline pH conditions, Ancitabine can be quantitatively converted into Cytarabine and can be used in the study of cancers such as colorectal cancer .

HY-111170

STA-9584	Microtubule/Tubulin	Cancer
STA-9584 is a potent vascular disrupting agent (VDA) that targets tubulin. STA-9584 exhibits potent antitumor activity in mouse xenograft model by selectively targeting microvasculature at both the center and periphery of tumors. STA-9584 can be used for research in prostate and breast cancer .

HY-175265

PQ32	c-Myc Ras Apoptosis	Cancer
PQ32 is an antitumor agent that targets c-MYC Pu27 and KRAS G-quadruplexes. PQ32 inhibits tumor cell proliferation, arrests the cell cycle at the G2 phase, and induces apoptosis. PQ32 inhibits the expression of c-MYC and KRAS genes. PQ32 can inhibit tumor growth in mice and is used in the study of lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, and other cancers .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-177733

MG-Lin3	Molecular Glues MicroRNA	Cancer
Lin28 degrader MG-Lin3 is a molecular glucose degrading agent that targets the Lin28 protein. Lin28 degrader MG-Lin3 significantly reduces the Renilla luciferase signal at 100 µM. Lin28 degrader MG-Lin3 inhibits the maturation of tumor microRNA let-7. Lin28 degrader MG-Lin3 can be used for cancer research .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-163545

Tc-Me2P	Drug Derivative	Cancer
Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .

Cat. No.	Nombre del producto

HY-L112

Chemotherapy Drug Library

156 compounds

Chemotherapy is one of the most common treatments for cancer. It can be used alone for some types of cancer or in combination with other treatments such as radiation or surgery. Chemotherapy drugs usually target cells at different phases of the cell cycle and inhibit tumor proliferation and avoid cancer cell invasion and metastasis. It is a cancer treatment method that kills cancer cells with drugs.

Chemotherapeutic agents can be classified into alkylating agents, antimetabolites, antimicrotubular agents, antibiotics, etc. according to the mechanism of action. MCE offers a unique collection of 156 chemotherapy drugs, which is a useful tool for cancer treatment research.

HY-L173

Anti-Ovarian Cancer Compound Library

2,817 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,817 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L213

Anti-Cancer Approved Drug Library

271 compounds

The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.

This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.

MCE has collected 271 small-molecule compounds with cancer indications, which are good tools for drug repurposing.

HY-L932V0

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

Macrocyclic compounds (≥12-atom cyclic small molecules/peptides) have unique physicochemical properties. They form preorganized conformations with high binding affinity/selectivity, target traditional small-molecule-inaccessible proteins, and bridge small-molecule drugs and biological agents. As key protein phosphorylation enzymes, kinases are linked to tumors, COPD, etc., and are critical therapeutic targets. Traditional small-molecule kinase inhibitors lack selectivity, causing off-target toxicity, low bioavailability, and acquired resistance. Macrocycles’ semi-rigid structure restricts conformations, boosts binding selectivity, optimizes pharmacokinetics, and makes macrocyclization a core kinase inhibitor optimization strategy.

Thousands of bioactive macrocycles were curated from ChEMBL. Via Transformer, macrocyclization was converted into a chemical language translation task, enabling end-to-end macrocycle generation from linear precursors with simplified inputs. Macformer achieves efficient, automated linear molecule macrocyclization via deep learning; generated macrocycles have diversity, novelty, biocompatibility, and cover broader chemical space.

MCE collected thousands of marketed/clinical kinase inhibitors, using their fragments for macrocyclization to generate derivatives. After evaluating synthetic accessibility and physicochemical properties, a million-scale virtual macrocyclic library was built for kinase-related virtual and AI-driven screening.

HY-L932V

Kinase Macrocyclic Compound Virtual Library

2,000,000 compounds

HY-L064

Glutamine Metabolism Compound Library

1,690 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Nombre del producto	Type

HY-145746

Sulfo-Cy5 azide

Fluorescent Dyes

Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-D1716

S0456	Fluorescent Dyes
S0456 is a raw material that plays a crucial role in the construction of the folate receptor-targeted near-infrared dye OTL 38 (HY-139579). S0456 is connected to the modified folic acid to form OTL 38, endowing OTL 38 with good optical properties, high affinity, and specificity. S0456 can be used in the research of tumor optical imaging agents .

HY-10227G

Bortezomib

PS-341; LDP-341; NSC 681239

Fluorescent Dyes

Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .

HY-D3353

PSMA-SulfoCy7

Fluorescent Dyes

PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a K_i of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .

Cat. No.	Nombre del producto	Type

HY-W020780

mPEG5000-Mal

mPEG5000-Maleimide

Biochemical Assay Reagents

mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses .

HY-W053583

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-172494

DSPE-PEG2000-iRGD	Biochemical Assay Reagents
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-155882

mPEG750-amine

mPEG750-NH2

Biochemical Assay Reagents

mPEG750-amine (mPEG750-NH2) is a chemical modification reagent for nanoparticles, capable of covalently binding to Ad-PVA to form Ad-PVA-PEG polymers. mPEG750-amine stabilizes gene delivery complexes by providing steric hindrance, reducing particle aggregation, while enhancing the water solubility and serum stability of the complex, reducing carrier cytotoxicity, and assisting in the efficient condensation of pDNA by cationic components to form nanoparticles that can be endocytosed by cells. mPEG750-amine can also be used to synthesize folate-conjugated polymer micelles for encapsulating the anticancer agent Camptothecin (HY-16560). Folate-conjugated polymer micelles are effective carriers for poorly soluble anticancer drugs, capable of avoiding macrophages and acting through folate receptor (FR)-mediated endocytosis to target tumor cells. mPEG750-amine can be applied to research in the field of non-viral gene delivery, as a component of gene delivery vectors, facilitating the safe and efficient delivery of nucleic acid drugs to target cells .

HY-W250149

Chlorophosphonazo III

Biochemical Assay Reagents

Chlorophosphonazo III is a cell membrane-permeable contrast agent and spectrophotometric reagent. Chlorophosphonazo III forms stable 1:1 complexes with intracellular calcium, magnesium, uranium, titanium, zirconium, thorium, scandium, equivalent actinides and protactinium. Chlorophosphonazo III generates photoacoustic signals correlated with Ca ²⁺ concentrations, which is applicable for imaging 3D tumor cell cultures and tumor spheroids. Chlorophosphonazo III exhibits no cytotoxicity, can be used for spectrophotometric detection of target ions, and the absorbance of its complexes remains stable for up to one week within the pH range of 2.2 to 7.0 .

HY-158067

Deferoxamine-DBCO

DFO-DBCO

Biochemical Assay Reagents

Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-W053583R

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-10227G

Bortezomib

PS-341; LDP-341; NSC 681239

Biochemical Assay Reagents

Cat. No.	Nombre del producto	Target	Research Area

HY-P0122

iRGD peptide 5+ Cited Publications c(CRGDKGPDC)	Integrin	Cancer
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.

HY-P10709

CREKA peptide	Collagen	Cardiovascular Disease Cancer
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-16532

Zoptarelin doxorubicin AEZS-108; AN-152	Peptide-Drug Conjugates (PDCs) GnRH Receptor	Cancer
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .

HY-P10579

123B9 1 Publications Verification	Ephrin Receptor	Cancer
123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a K_d value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .

HY-P10792

HER2-targeted peptide H6F	EGFR	Cancer
HER2-targeted peptide H6F is a HER2 targeting peptide that binds to HER2 to target breast cancer cells, with the amino acid sequence YLFFVFER. The HER2-targeted peptide H6F can be conjugated with the bifunctional chelating agent hydrazinonicotinamide (HYNIC) for radiolabeling with 99mTc. Single-photon emission computed tomography (SPECT) imaging shows that the labeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MBA-453 tumor-bearing mice models. The HER2-targeted peptide H6F can be used for tumor molecular imaging studies .

HY-P4116A

pH-Low Insertion Peptide TFA pHLIP TFA	Peptides	Metabolic Disease Cancer
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .

HY-P10775A

BT1769 acetate	MMP	Cancer
BT1769 acetate is a conjugate and antitumor agent targeting MT1-MMP, with a K_d value of 3.35 nM against human targets. BT1769 acetate exhibits favorable pharmacokinetic properties. BT1769 acetate specifically binds to MT1-MMP via its bicyclic peptide component, delivering the cytotoxic agent MMAE (HY-15162) to antigen-expressing cells. It effectively inhibits tumor growth, induces complete responses, and significantly prolongs event-free survival in osteosarcoma patient-derived xenograft models. BT1769 acetate shows extremely low activity in Ewing sarcoma models and can be used in osteosarcoma-related research .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P10052

CBO-P11	VEGFR	Cancer
CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .

HY-P3196

Tozuleristide	Peptides	Cancer
Tozuleristide is a tumor-targeting agent covalently conjugated to a derivative of the near-infrared fluorescent dye indocyanine green (ICG). Tozuleristide has the ability to penetrate the blood-brain barrier. Tozuleristide can be used in research related to fluorescence-guided surgery (FGS) .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

HY-P11781A

Cys-HW12	Drug Derivative	Cancer
Cys-HW12 is a random peptide containing an N-terminal cysteine. Cys-HW12 can be coupled via the thiol group of Cys. Cys-HW12 can serve as a control for GE11 (HY-P10128)-conjugated mixed micelles targeting EGFR, and also functions as a cytotoxic agent, cellular uptake inhibitor, and tumor growth inhibitor. Cys-HW12 is applicable to pancreatic cancer-related research .

HY-P11781B

Cys-HW12 TFA	Drug Derivative	Cancer
Cys-HW12 TFA is a random peptide containing an N-terminal cysteine and derivative of HW12 (HY-P11781). Cys-HW12 TFA can be coupled via the thiol group of Cys. Cys-HW12 TFA can serve as a control for GE11 (HY-P10128)-conjugated mixed micelles targeting EGFR, and also functions as a cytotoxic agent, cellular uptake inhibitor, and tumor growth inhibitor. Cys-HW12 TFA is applicable to pancreatic cancer-related research .

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P9968

Nimotuzumab 1 Publications Verification h-R3	EGFR	Cancer
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P99284

Dalotuzumab 1 Publications Verification MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .

HY-P991742

LY4101174 Antibody 15A7.5; ETx-22 Antibody	ADC Antibody	Cancer
LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .

HY-P9968A

Nimotuzumab (powder)	EGFR	Cancer
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a K_D value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .

HY-P991395

TQB2618	Tim3	Cancer
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .

HY-P991384

DX-2240	Tie	Cancer
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

HY-P992340

CTB006	Radionuclide-Drug Conjugates (RDCs) TNF Receptor	Cancer
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. ¹⁷⁷Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while ⁸⁹Zr- or ¹⁷⁷Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .

HY-P992449

REGN2878 PRLR ADC antibody	ADC Antibody	Cancer
REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (K_D) of 1.05 nM and an IC₅₀ of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .

HY-P992060

Anti-Mouse CD20 Antibody (18B12)	CD20 NF-κB	Inflammation/Immunology Cancer
Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8 ⁺ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury .

Cat. No.	Nombre del producto	Chemical Structure

HY-10227S

Bortezomib-d8

Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .

HY-13762S

Tesmilifene-d4
Tesmilifene-d4 is the deuterium labeled Tesmilifene (HY-13762). Tesmilifene is an antihistamine agent and a chemical sensitizer. Tesmilifene targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene overcomes multidrug resistance .

HY-W766368

C6 Ceramide-13C2,d2

C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Cat. No.	Nombre del producto		Classification

HY-145746

Sulfo-Cy5 azide		Azide Labeling and Fluorescence Imaging
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm) .

HY-158067

Deferoxamine-DBCO DFO-DBCO		DBCO
Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-178962

Antitumor agent-207		Alkynes
Antitumor agent-207 (compound 10K) is a Pt(IV)-NO prodrug with high lipid solubility, good stability, and excellent tumor targeted release ability. Antitumor agent-207 has significant anti proliferative activity in various cells such as TE-1 (IC₅₀ = 1.79 μM), TE-10 (IC₅₀ = 1.95 μM), KYSE-30 IC₅₀ = 5.99 μM), KYSE-520 (IC₅₀ = 5.53 μM) cells. Antitumor agent-207 can significantly enhance intracellular Pt accumulation and DNA platformization levels, and effectively release NO. Antitumor agent-207 can be used for research on cancers such as esophageal cancer .

Cat. No.	Nombre del producto		Classification

HY-172494

DSPE-PEG2000-iRGD		Pegylated Lipids
DSPE-PEG2000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG2000-iRGD can be used for agent delivery .

HY-155882

mPEG750-amine mPEG750-NH2		Polymers
mPEG750-amine (mPEG750-NH2) is a chemical modification reagent for nanoparticles, capable of covalently binding to Ad-PVA to form Ad-PVA-PEG polymers. mPEG750-amine stabilizes gene delivery complexes by providing steric hindrance, reducing particle aggregation, while enhancing the water solubility and serum stability of the complex, reducing carrier cytotoxicity, and assisting in the efficient condensation of pDNA by cationic components to form nanoparticles that can be endocytosed by cells. mPEG750-amine can also be used to synthesize folate-conjugated polymer micelles for encapsulating the anticancer agent Camptothecin (HY-16560). Folate-conjugated polymer micelles are effective carriers for poorly soluble anticancer drugs, capable of avoiding macrophages and acting through folate receptor (FR)-mediated endocytosis to target tumor cells. mPEG750-amine can be applied to research in the field of non-viral gene delivery, as a component of gene delivery vectors, facilitating the safe and efficient delivery of nucleic acid drugs to target cells .

HY-177571

Sgc8c-M Sgc8c-VcMMAE		Aptamers
Sgc8c-M is a *PTK7*-targeted aptamer-drug conjugate (ApDC). Sgc8c-M is composed of the classic PTK7-specific aptamer Sgc8c, a cathepsin B (CTSB)-cleavable valine-citrulline (VC)-based linker, and the potent antimitotic agent Monomethyl auristatin E (MMAE) (HY-15162) as the payload. Sgc8c-M inhibits the growth of PTK7-overexpressing cancer cells. Sgc8c-M can be used for the study of PTK7-expressing advanced solid tumors .

Targets Recommended: Large Tumor Suppressor (LATS) TNF Receptor BRK

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-10227G

Bortezomib PS-341; LDP-341; NSC 681239	Proteasome NF-κB Apoptosis Autophagy TREM receptor	Cancer
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: